^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    glesatinib (MGCD265)

    i
    Company:
    BMS
    Drug class:
    VEGFR inhibitor, c-MET inhibitor, AXL inhibitor
    Related drugs:
    Apply
    Phase 2 Study of MGCD265 in Patients With Non-Small Cell Lung Cancer With Activating Genetic Alterations in MET (NCT02544633)
    Phase 2
    Mirati Therapeutics Inc.
    Completed
    Last update posted :
    03/04/2020
    Initiation :
    10/01/2015
    Primary completion :
    04/30/2018
    Completion :
    01/01/2019
    MET
    |
    MET amplification • MET mutation
    |
    glesatinib (MGCD265)
    Safety Study of Oral MGCD265 Administered Without Interruption to Subjects With Advanced Malignancies (NCT00697632)
    Phase 1
    Mirati Therapeutics Inc.
    Completed
    Last update posted :
    02/12/2019
    Initiation :
    06/01/2008
    Primary completion :
    09/01/2018
    Completion :
    01/01/2019
    MET • AXL
    |
    MET amplification • MET mutation • MET expression • AXL expression
    |
    glesatinib (MGCD265)